Nastech Pharmaceutical (Nastech) is engaged in a variety of preclinical and clinical research and development activities to identify and develop viable product candidates in therapeutic areas, including osteoporosis, obesity, ...

Dyax discovers, develops and commercializes biopharmaceuticals primarily in the areas of inflammation and oncology. The company, through its proprietary drug discovery technology, known as phage display, identifies antibody, small ...

Auxilium Pharmaceuticals (Auxilium) is a specialty biopharmaceutical company engaged in developing and marketing products in the areas of urology, endocrinology and orthopedics. The company markets Testim, a testosterone replacement ...

Roche Holding, a holding company, is one of the leading research-focused healthcare groups in the world. The group specializes in the discovery, development and commercialization of therapeutics for life-threatening ...

Sanofi-Aventis is an international pharmaceutical group engaged in the research, development, manufacture and marketing of pharmaceutical products for sale principally in the prescription market. In terms of ethical pharmaceutical ...

Schering-Plough Corporation (Schering-Plough) discovers, develops, manufactures and markets medical therapies and treatments. The company focuses on discovery, development and manufacturing pharmaceuticals and has products marketed in over 120 countr... ...

Maxygen is a biotechnology company focused on discovery and development of next generation protein pharmaceuticals for the treatment of disease and serious medical conditions. It is headquartered in Redwood ...

Amylin Pharmaceuticals (Amylin) engages in the discovery, development and commercialization of potential drug candidates for the treatment of diabetes and obesity. The company primarily focuses on investigating the potential ...

The company primarily operates in the US. It is headquartered in Fort Worth, Texas and employs about 270 people. As the company is a subsidiary of Virbac Group, it ...

The group recorded revenues of E945.3 million during the fiscal year ended December 2006, an increase of 6.5% over 2005. The operating profit of the group was E187.2 million ...

The company recorded revenues of E2,281 million during the fiscal year ended December 2006, an increase of 2.3% over 2005. The operating profit of the company was E130.2 million ...

The company recorded revenues of E1,000.4 million during the fiscal year ended December 2006, an increase of 1% over 2005. The operating profit was E49.5 million in fiscal year ...

The company recorded revenues of £6,928 million during the fiscal year ended December 2005, and an increase of 21% over 2004. The operating profit of the company during fiscal ...

The company recorded revenues of $916.4 million during the fiscal year ended December 2006. The operating loss of the company was $214.8 million during fiscal year 2006. The net ...

The company recorded revenues of $343 million during the fiscal year ended December 2006, an increase of 22.7% over 2005. The operating loss of the company was $31 million ...

The company recorded revenues of $1,021.7 million during the fiscal year ended December 2006, an increase of 21.3% over 2005. The increase in the revenues was primarily due to ...

The company recorded revenues of $26 million during the fiscal year ended December 2006, an increase of 36.8% over 2005. The operating loss of the company was $237 million ...

The company recorded revenues of $49 million during the fiscal year ended December 2006, a decrease of 5.5% over 2005. The operating loss of the company was $198 million ...

The company recorded revenues of $216.4 million during the fiscal year ended December 2006, an increase of 34.5% over 2005. The operating loss of the company was $229 million ...

It is headquartered in North Amityville, New York and employs about 255 people. ...